Editas Medicine Inc (EDIT)
NASDAQ
News
Market Data
Register for streaming realtime charts, analysis tools, and prices.
Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR... Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company's only operating segment is developing and commercializing genome editing technology. Show more
Ask ADVFN Intelligence (AI)
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following...
Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine’s proprietary targeted LNP in a key step to developing a...
Achieved in vivo preclinical proof of concept of hematopoietic stem and progenitor cell editing by utilizing Editas Medicine’s proprietary targeted LNP as a key step forward toward developing a...
CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and...
CAMBRIDGE, Mass., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a Company-sponsored webinar...
CAMBRIDGE, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced the sale of certain future license fees and other...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.19 | 6.59722222222 | 2.88 | 3.4 | 2.8 | 2420862 | 3.21608209 | CS |
| 4 | -0.17 | -5.24691358025 | 3.24 | 3.8 | 2.7 | 2130085 | 3.22454562 | CS |
| 12 | -1.06 | -25.6658595642 | 4.13 | 4.15 | 2.7 | 1975161 | 3.44518918 | CS |
| 26 | -2.36 | -43.4622467772 | 5.43 | 6.69 | 2.7 | 1976932 | 4.35428238 | CS |
| 52 | -4.45 | -59.1755319149 | 7.52 | 11.69 | 2.7 | 1939242 | 6.33572581 | CS |
| 156 | -35.26 | -91.9906078789 | 38.33 | 38.57 | 2.7 | 1812992 | 10.50592612 | CS |
| 260 | -17.73 | -85.2403846154 | 20.8 | 99.95 | 2.7 | 1680897 | 22.96059154 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
